IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.81
+2.92%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$33.33
From 52W high−20.41%
Volume765750.00
Market cap$3.26B
P/E (TTM)—
P/S (TTM)13.9x
Div yield—
Key dataOct 19, 2026
Open
$33.33
From 52W high
−20.41%
Volume
765750.00
Market cap
$3.26B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.6x
P/E (TTM)
—
RSI (14)
35.4
MomentumView details →
1D Return
+2.92%
YTD Return
−1.94%
SummaryUpdated Jun 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.
Similar companies
Latest newsMore news →
IDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.22d agoIDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.62d ago